Supplementary Tables from A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies
Year: 2023
Type: supplementary-materials
Abstract: Table S1: Human melanoma cell lines and mutation status Table S2: Differences in PD-L1 and CD155 drug responses between BRAF- and NRAS-mutant cell lines Table S3: Differences in HLA-I and CD73 drug responses between BRAF- and NRAS-mutant cell lines Table S4: Differences in NGFR and CD55 drug responses between BRAF- and NRAS-mutant cell lines Table S5: Differences in PD-L1, CD155, and HLA-I drug responses in BRAF-mutant cell lines Table S6: Differences in CD73, NGFR, and CD55 drug responses in BRAF- mutant cell lines Table S7: Differences in PD-L1, CD155, and HLA-I drug responses in NRAS- mutant cell lines Table S8: Differences in CD73, NGFR, and CD55 drug responses in NRAS- mutant cell lines Table S9: Fractional product analysis of Reg, anti-CD40, and STING agonist in vivo results Table S10: Fractional product analysis of Reg and adoptive cell transfer in vivo results
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362560682